Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase I Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV⁺ Head and Neck Cancer

Cue Biopharma, Inc. provided a clinical update on its most advanced asset, CUE-101, representative of the CUE-100 series of interleukin 2 (IL-2)-based biologics. It is designed to activate and expand HPV16 tumor-specific T cells by presenting two signals to T cells.